10:39 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the 12-month period ended December 31, 2018. Unless otherwise noted, all amounts are in U.S. dollars and are prepared in accordance with International Financial Reporting Standards. Total revenues of $7.4 million for the year, including $7.0 million of product revenues. The Company incurred a 2018 net loss of $18.8 million or $(0.08) per share compared to $8.6 million or $(0.04) for the same prior-year periods. Acerus Pharmaceuticals Corporation
shares T.ASP are trading down $0.005 at $0.14.
